Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 82

recruiting
3 987
countries
28
conditions
2 109

990 trials match your criteria

Renal cell carcinoma

Not recruiting

Study Comparing Tivozanib and Nivolumab Combination to Tivozanib Alone in Patients with Renal Cell Carcinoma After Previous Immune Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Dimethyl Fumarate for Children Aged 10-17 with Relapsing-Remitting Multiple Sclerosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Dimethyl Fumarate

Sarcoma

Not recruiting

Study on the Effectiveness of Nivolumab, Ipilimumab, and Pazopanib in Patients with Advanced Rare Sarcomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab

Breast cancer+2

Not recruiting

Study of Durvalumab, Olaparib, and Fulvestrant for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer with Specific Genetic Alterations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab

Chondrosarcoma

Not recruiting

Study of INBRX-109 (ozekibart) compared to placebo in adults with unresectable or metastatic chondrosarcoma - a rare bone cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide

Hodgkin's disease+6

Not recruiting

Study of Cobolimab and Dostarlimab for Children and Young Adults with Newly Diagnosed or Relapsed/Refractory Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Cobolimab

Squamous cell carcinoma of head and neck

Not recruiting

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab

Cervix carcinoma

Not recruiting

Study on Atezolizumab, Bevacizumab, and Chemotherapy for Patients with Advanced Cervical Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Acute kidney injury

Not recruiting

Study on the Effects of Irbesartan After Acute Kidney Injury in Patients Discharged from ICU

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Irbesartan

Acute myeloid leukaemia

Not recruiting

Study on Improving Survival in Acute Myeloid Leukemia for Adults Aged 18-60 Using Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cytarabine

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.